# A Phase 2 Study of HX301 in Patients with High-grade Giloma

Source: https://onco.cc/trials/nct06703255/  
OnCo record `nct06703255` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.

## Summary

A Phase 2 Study of HX301 in Patients with High-grade Giloma is a phase 1/2 interventional study registered as NCT06703255 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 72 participants planned, started 2025-01-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: HX301+/Temozolomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06703255
- Phase: 1/2
- Setting: A Phase IIa Clinical Study of HX301 Alone or in Combination with Temozolomide in Patients with High-Grade Glioma (Grade III and IV)
- Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT06703255: https://clinicaltrials.gov/study/NCT06703255

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Hangzhou Hanx Biopharmaceuticals](https://onco.cc/companies/hangzhou-hanx-biopharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06703255.json